Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
67.53
+0.30 (0.45%)
Sep 18, 2024, 4:00 PM EDT - Market closed

Company Description

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.

It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.

In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.

The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation
Edwards Lifesciences logo
Country United States
Founded 1958
IPO Date Mar 27, 2000
Industry Medical Devices
Sector Healthcare
Employees 19,800
CEO Bernard Zovighian

Contact Details

Address:
One Edwards Way
Irvine, California 92614
United States
Phone 949 250 2500
Website edwards.com

Stock Details

Ticker Symbol EW
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001099800
CUSIP Number 28176E108
ISIN Number US28176E1082
Employer ID 36-4316614
SIC Code 3842

Key Executives

Name Position
Bernard J. Zovighian Chief Executive Officer and Director
Scott B. Ullem Corporate Vice President and Chief Financial Officer
Donald E. Bobo Jr. Corporate Vice President of Strategy and Corporate Development
Larry L. Wood Corporate Vice President and Group President of TAVR and Surgical Structural Heart
Andrew M. Dahl Principal Accounting Officer, Senior Vice President and Corporate Controller
Dr. Todd J. Brinton FACC, M.D. Corporate Vice President of Advanced Technology and Chief Scientific Officer
Mark Wilterding Vice President of Investor Relations
Arnold A. Pinkston Corporate Vice President and General Counsel
Dirksen J. Lehman Corporate Vice President of Public Affairs
Christine Z. McCauley Corporate Vice President of Human Resources

Latest SEC Filings

Date Type Title
Sep 3, 2024 8-K Current Report
Aug 20, 2024 144 Filing
Aug 14, 2024 144 Filing
Jul 31, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jul 31, 2024 10-Q Quarterly Report
Jul 24, 2024 8-K Current Report
Jul 15, 2024 8-K Current Report
Jul 11, 2024 144 Filing
Jul 10, 2024 8-K Current Report
Jun 20, 2024 144 Filing